Compare · NVO vs XLO
NVO vs XLO
Side-by-side comparison of Novo Nordisk A/S (NVO) and Xilio Therapeutics Inc. (XLO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and XLO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 3585.8x XLO ($54.6M).
- Over the past year, NVO is down 43.0% and XLO is down 17.2% - XLO leads by 25.8 points.
- XLO has been more active in the news (10 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 7 for XLO).
- Company
- Novo Nordisk A/S
- Xilio Therapeutics Inc.
- Price
- $43.88-0.20%
- $7.95+2.71%
- Market cap
- $195.92B
- $54.6M
- 1M return
- -6.80%
- +2.45%
- 1Y return
- -43.03%
- -17.25%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 10
- Recent ratings
- 25
- 7
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Xilio Therapeutics Inc.
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest XLO
- SEC Form 4 filed by Director Shannon James Samuel
- SEC Form 4 filed by Director Bonstein Sara
- SEC Form 4 filed by Director Curran Daniel J.
- SEC Form 4 filed by Director Xu Yuan
- SEC Form 4 filed by Director Ross Robert W.
- SEC Form 4 filed by Director Bello Akintunde Olatokumbo
- SEC Form 4 filed by Director Brennan Aoife
- Xilio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form EFFECT filed by Xilio Therapeutics Inc.
- Amendment: SEC Form S-3/A filed by Xilio Therapeutics Inc.